SSc–nonPAH (n = 19) | SSc–PAH (n = 21) | ||
PAH rest (n = 13) | PAH exercise (n = 8) | ||
Time since clinical diagnosis of SSc, year (95% CI) | 3.7 (1.3–10.7) | 2.8 (1.6–5.0) | 4.2 (1.6–27.8)* |
Limited cutaneous SSc/diffuse cutaneous SSc | 17/2 | 12/1 | 7/1† |
Antinuclear antibody (%) | 17 (90) | 13 (100) | 7 (88)† |
Anticentromere antibody (%) | 11 (58) | 7 (54) | 1 (13)† |
Anti-topoisomerase antibody (%) | 2 (11) | 0 | 3 (38)‡ |
Anti-RNP antibody (%) | 0 | 3 (23) | 1 (13)† |
Pulmonary fibrosis in the dorsobasal fields of the lungs on HRCT thorax (%) | 4 (21) | 8 (62) | 8 (100)‡ |
Total lung capacity % of predicted (SD) | 96.8 (8.4) | 91.1 (10.3) | 91.8 (13.9)* |
Diffusing capacity for cardiac output <70% of predicted (%) | 8 (42) | 12 (86) | 6 (75)‡ |
HRCT, high-resolution computed tomography; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis; SSC–nonPAH, patients with SSc but no PAH; SSC–PAH, patients with SSc and PAH.
*Differences not significant between categories (ANOVA).
†Differences not significant between categories (χ2).
‡Differences significant (p<0.05) between categories (χ2).